Satish Shanbhag is an Oncology physician affiliated with Florida Cancer Specialists & Research Institute. OpenAlex indexes 61 publications with 3,089 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2370 Market Dr
Fleming Island, FL 320034326
Telephone
904-264-6201Provider last certified this registry record 14 May 2020.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20257 payments
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- Merck Sharp & Dohme LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
59.9%Iron, parenteral preparations59.7%Ferric carboxymaltose100%Part B, office-administered≥19 patientsFactor Xa inhibitor0.2%Eliquis65%Xarelto36%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
25.5%Other antiemetics18.3%Fosaprepitant100%Part B, office-administered≥16 patientsSerotonin-3 Receptor Antagonist7.1%Granisetron hydrochloride61%Palonosetron hcl37%Ondansetron Hcl2%Part D + Part B≥25 patients+ 3 more classes in this area
Musculoskeletal
7.1%RANK Ligand Inhibitor7.1%Denosumab100%Part B, office-administered≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patient-Reported Outcomes After Ferric Carboxymaltose Treatment for Iron Deficiency Anemia: A Prospective Observational Study
International Journal of General Medicine
2023 - The Impact of an Antithrombotic Stewardship Program on Heparin-Induced Thrombocytopenia Management
Journal of Pharmacy Practice
2022 - Hemostatic and antithrombotic stewardship programs: A toolkit for program implementation
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
2022 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Monk, MD
Florida Cancer Specialists & Research Institute
Ivor Percent, MD
Florida Cancer Specialists & Research Institute
Bradford Perez, MD
Florida Cancer Specialists & Research Institute
Scott Lunin, MD
Florida Cancer Specialists & Research Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”